Blood Concentrations of Osimertinib and Its Active Metabolites: Impact on Treatment Efficacy and Safety
Anticancer Research · 2025
DOI: 10.21873/anticanres.17627 ↗Kurz gefasst
Fachartikel in der Zeitschrift Anticancer Research, 2025. Verfasst von Takae Okuno und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology and Respiratory Medicine, Department of Internal Medicine, Shimane University Faculty of Medicine, Shimane, Japan. Hauptthemen laut MEDLINE: Acrylamides, Aniline Compounds, Lung Neoplasms, Carcinoma, Non-Small-Cell Lung. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Medical Oncology and Respiratory Medicine, Department of Internal Medicine, Shimane University Faculty of Medicine, Shimane, Japan.
- Department of Pharmacy, Shimane University Hospital, Shimane, Japan.
- Division of Medical Oncology and Respiratory Medicine, Department of Internal Medicine, Shimane University Faculty of Medicine, Shimane, Japan; okimoto@med.shimane-u.ac.jp.
Zitieren
APA
Okuno, T., Hongoh, M., Tanino, R., Okimoto, T., Tsubata, Y., & Isobe, T. (2025). Blood Concentrations of Osimertinib and Its Active Metabolites: Impact on Treatment Efficacy and Safety. Anticancer Research. https://doi.org/10.21873/anticanres.17627
Vancouver
Okuno T, Hongoh M, Tanino R, Okimoto T, Tsubata Y, Isobe T. Blood Concentrations of Osimertinib and Its Active Metabolites: Impact on Treatment Efficacy and Safety. Anticancer Research. 2025. doi:10.21873/anticanres.17627
BibTeX
@article{Okuno2025,
author = {Okuno, Takae and Hongoh, Masafumi and Tanino, Ryosuke and Okimoto, Tamio and Tsubata, Yukari and Isobe, Takeshi},
title = {Blood Concentrations of Osimertinib and Its Active Metabolites: Impact on Treatment Efficacy and Safety},
journal = {Anticancer Research},
year = {2025},
doi = {10.21873/anticanres.17627}
}
EUVIMED